



FRONTIER THERAPEUTICS

www.frontiertherapeuticsnw.com

Jason Greer
Executive Manager
406.370.7177
jason@frontiertherapeuticsnw.com

January 8, 2016

**VIA EMAIL
CONFIRMATION BY FEDEX**

Ms. Terri Shoemaker
President & CEO
Medac Pharma, Inc.
29 North Wacker Drive, Suite 704
Chicago, IL 60606
tshoemaker@medacpharma.com

Re: Rasuvo[®] and Orange Book-Listed U.S. Patent No. 8,664,231

Dear Ms. Shoemaker:

My company, Frontier Therapeutics, LLC, is a pharmaceutical company focused on commercializing both generic and innovative drug products. Frontier has uniquely positioned itself to achieve its strategic objectives through its industry relationships.

Frontier is currently focused on identifying branded products that it believes are artificially propped up by Orange Book-listed patents that are likely invalid and/or unenforceable. During this process, Frontier has identified significant weaknesses with U.S. Patent No. 8,664,231, which has been listed on the Orange Book for Medac's product, Rasuvo[®]. Enclosed for your review is a draft petition for *inter partes* review of the '231 Patent (IPR), which includes five invalidity grounds demonstrating issued claims 1-22 are anticipated and/or obvious over the prior art. As you will see, these five invalidity positions mirror the grounds for which the Patent Trials and Appeals Board (PTAB) previously instituted a review of the '231 Patent. *See Petition for Inter Partes Review by Antares Pharma Inc. et al.*, IPR 2014-01091, Paper No. 7, January 6, 2015.

Given the strength of its invalidity positions, and the fact that the PTAB previously instituted an *inter partes* review of the '231 Patent, Frontier is confident its IPR will demonstrate a reasonable likelihood of invalidity, and that the PTAB will again institute an IPR of the '231 Patent. When that occurs, Frontier intends to approach its development partners to prepare and file an ANDA for Rasuvo[®].

Medac Exhibit 2001



FRONTIER THERAPEUTICS

Before finalizing and filing its IPR petition, Frontier would like to explore the possibility of reaching an amicable resolution to this matter. Given the noted vulnerabilities of the '231 Patent and the current challenges Medac has experienced with the prosecution of other key patent applications in its portfolio (notably, U.S. Application No. 14/195,117), we hope you agree that a confidential and expeditious resolution would be in the best interest of Medac and its stakeholders.

Now that Frontier has disclosed the accompanying copyrighted draft of its IPR, time is of the essence. If you are interested in holding settlement talks, please contact Frontier's legal counsel, Jim Johnston, before the **close of business on January 15, 2016**. You may reach Mr. Johnston at (425) 890-2367 or jjohnston@johnston-law.com.

Sincerely,

Jason Greer

cc:

Jim Johnston (jjohnston@johnston-law.com)

William Cronin (wcronin@correronin.com)

Frank DiGiglio (fsd@ssmp.com)

Edward Grolz (egrolz@ssmp.com)